Related Experiment Video

Updated: Aug 16, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approach to

Leszek Tylicki1, Wojciech Larczynski, Bolesław Rutkowski

  • 1Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, Poland. leszek.tylicki@amg.gda.pl

Kidney & Blood Pressure Research
|August 30, 2005
PubMed

Insights

Renin-angiotensin-aldosterone system (RAAS) blockade, using ACE inhibitors or ARBs, is key for slowing chronic kidney disease progression. Early initiation and maximal doses are crucial for optimal renoprotection in proteinuric nephropathies.

Area of Science:

  • Nephrology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • The renin-angiotensin-aldosterone system (RAAS) plays a critical role in regulating blood pressure and fluid balance.
  • Dysregulation of the RAAS is implicated in the progression of various chronic kidney diseases (CKDs).
  • RAAS blockade represents a cornerstone therapy for managing proteinuric nephropathies.

Purpose of the Study:

  • To review the evidence-based approach for utilizing RAAS-inhibiting agents in kidney diseases.
  • To outline treatment strategies for RAAS blockade in diverse clinical scenarios of nephropathy.
  • To discuss future perspectives on RAAS blockade for renal protection.

Main Methods:

  • Systematic review of existing literature on RAAS blockade in nephropathies.
  • Analysis of clinical trial data regarding the efficacy of ACE inhibitors (CEIs) and ARBs.
  • Evidence-based guideline formulation for RAAS inhibitor use in proteinuric kidney diseases.

Main Results:

  • RAAS blockade with CEIs or ARBs is recommended for all patients with chronic proteinuric nephropathy, regardless of diabetic status or baseline renal function.
  • Early initiation of therapy before overt proteinuria or reduced kidney function enhances renoprotection.
  • High-dose CEIs and ARBs are necessary to maximize proteinuria reduction and achieve blood pressure targets (<130/80 mmHg, or <125/75 mmHg for those with proteinuria >1 g/24h).

Conclusions:

  • RAAS blockade is the most effective strategy for delaying the progression of chronic nephropathies.
  • Combination therapy with CEIs and ARBs is indicated for patients with non-diabetic proteinuric nephropathies unresponsive to monotherapy.
  • Optimal management involves early, high-dose RAAS inhibition tailored to individual patient characteristics and proteinuria levels.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...